The FDA has an ongoing Class II recall covering multiple strengths of semaglutide multi-dose vials for subcutaneous injection from a single outsourcing facility. The stated reason is the presence of particulate matter, identified as nylon/polyamide and silk/proteinaceous-type material. Class II means the FDA judges that use may cause temporary or medically reversible harm, with serious harm unlikely.
This is a compounding and manufacturing problem, not a signal about semaglutide. Nothing here changes the evidence for the licensed product. What it does change is the question you ask a patient who reports they are on a weekly injection: where did the vial come from, and is it a licensed pen or a compounded multi-dose vial.
A separate ongoing Class II recall covers a ready-to-use human insulin in sodium chloride infusion presentation for manufacturing deviations, relevant to inpatient pharmacy stock rather than to outpatient prescribing.
- Ask patients on GLP-1 therapy whether they are using a licensed pen or a compounded multi-dose vial, and record the answer.
- Advise anyone holding a compounded vial to inspect it against the light and not to inject visibly cloudy or particle-containing solution.
- Check inpatient pharmacy stock of ready-to-use insulin infusion bags against current recall notices.
- Report suspected injection-site reactions from compounded product rather than attributing them to the drug class.
- Compounded GLP-1 vials are a US supply phenomenon; the Indian relevance is the parallel grey market in unlicensed and repackaged product, which carries the same inspection advice.
Why it matters
A recall of the compounded supply chain does not reach patients through the usual prescribing channel, so it only surfaces if you ask where the drug came from.
Don't overread it
A Class II recall for particulate matter is a manufacturing finding about specific lots, not a safety signal against semaglutide.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free